Aug. 3, 2011 -- A painless urine test could soon help doctors tell when a high prostate-specific antigen (PSA) level means a dangerous cancer or when it’s a sign of a more benign condition that may not need further treatment, a new study shows.
The test looks for a genetic mistake that’s present in about half of all cases of prostate cancer.
This mistake, a case of two genes that come together and fuse, doesn’t appear to occur anywhere else in the body, or even in precancerous conditions, making it a highly specific marker for the disease.
When the genes fuse, says study researcher Scott A. Tomlins, MD, PhD, a pathologist at the University of Michigan Health System, in Ann Arbor, it’s a lot like flipping a switch. “And that gene, when it’s turned on, can cause cancer.”
Yet high PSA levels, over four, typically lead to a biopsy, which can cause discomfort, anxiety, and in rare cases, lead to complications like infections. Biopsies are also expensive, costing somewhere between $500 and $1,500. Researchers say that right now, when PSA levels are elevated, it’s up to patients and their doctors to figure out what to do next.
“There really aren’t very good tools to utilize to help make that decision,” Tomlins says. “We wanted to see if our urine markers could be useful in that situation.”
Testing for Prostate Cancer Biomarkers
For the study, which is published in the journal Science Translational Medicine, researchers tested the urine of 1,312 men with elevated PSA levels who had gone on to have needle biopsies or surgery to remove their prostates.
The test uses strands of artificially created oligonucleotides, the building blocks of DNA and RNA, which are built to match the code of the fused gene, which is called TMPRSS2:ERG.